| Phase 11 trial |
|
Phase 1
|
NCT00981669 |
Mar 2009 → Mar 2010 |
Rotavirus infection |
Butantan Institute |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT02482636 |
Aug 2015 → Nov 2017 |
infectious disease |
University of Oxford |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01049035 |
Dec 2009 → Feb 2012 |
meningitis, meningococcal infection |
Sanofi Pasteur, a Sanofi Company |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00346892 |
Nov 2001 → Mar 2003 |
Rotavirus infection |
GlaxoSmithKline |
Completed
|
No outcome recorded
|
| Phase 43 trials · 1 met primary · 1 missed |
|
Phase 4
|
NCT02153866 |
Dec 2013 → May 2014 |
Rotavirus infection |
Sichuan Center for Disease Control and Prevention |
Unknown
|
No outcome recorded
|
|
Phase 4
|
NCT01616693 |
Jul 2012 → Jul 2013 |
— |
PATH |
Completed
|
Met primary
|
|
Phase 4
|
NCT01199874 |
Apr 2011 → Sep 2012 |
Rotavirus infection |
PATH |
Completed
|
Missed primary
|
| Comparator or background therapy3 trials |
|
Phase 3
|
NCT06397768 Background |
May 2024 → Sep 2025 |
respiratory syncytial virus infectious disease |
Sanofi Pasteur, a Sanofi Company |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 3
|
NCT05794230 Background |
Mar 2023 → Nov 2025 |
meningococcal infection |
Sanofi Pasteur, a Sanofi Company |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT03673462 Background |
Sep 2018 → Mar 2023 |
— |
Sanofi Pasteur, a Sanofi Company |
Completed
|
No outcome recorded
|